Insulin-like growth factor I (IGF-I) and its type I receptor (IGF-IR) play significant roles in tumorigenesis and in immune response. Here, we wanted to know whether an RNA interference approach targeted to IGF-IR could be used for specific antitumor immunostimulation in a breast cancer model. For that, we evaluated short interfering RNA (siRNAs) for inhibition of in vivo tumor growth and immunological stimulation in immunocompetent mice. We designed 2′-O-methyl-modified siRNAs to inhibit expression of IGF-IR in two murine breast cancer cell lines (EMT6, C4HD). Cell transfection of IGF-IR siRNAs decreased proliferation, diminished phosphorylation of downstream signaling pathway proteins, AKT and ERK, and caused a G0/G1 cell cycle block. The IGF-IR silencing also induced secretion of two proinflammatory cytokines, TNF- α and IFN-γ. When we transfected C4HD cells with siRNAs targeting IGF-IR, mammary tumor growth was strongly delayed in syngenic mice. Histology of developing tumors in mice grafted with IGF-IR siRNA treated C4HD cells revealed a low mitotic index, and infiltration of lymphocytes and polymorphonuclear neutrophils, suggesting activation of an antitumor immune response. When we used C4HD cells treated with siRNA as an immunogen, we observed an increase in delayed-type hypersensitivity and the presence of cytotoxic splenocytes against wild-type C4HD cells, indicative of evolving immune response. Our findings show that silencing IGF-IR using synthetic siRNA bearing 2′-O-methyl nucleotides may offer a new clinical approach for treatment of mammary tumors expressing IGF-IR. Interestingly, our work also suggests that crosstalk between IGF-I axis and antitumor immune response can mobilize proinflammatory cytokines.
References
[1]
Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20–47.
[2]
Lann D, LeRoith D (2008) The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia 13: 371–379.
[3]
Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics 6: 1–12.
[4]
Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009–3021.
[5]
Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107: 873–877.
[6]
Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, et al. (2010) Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 70: 206–218.
[7]
Lecosnier S, Cordier C, Simon P, Fran？ois J-C, Saison-Behmoaras TE (2011) A steric blocker of translation elongation inhibits IGF-1R expression and cell transformation. FASEB J. doi:10.1096/fj.10-169540.
[8]
Oussedik K, Francois JC, Halby L, Senamaud-Beaufort C, Toutirais G, et al. (2010) Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J 24: 2235–2244.
[9]
Shaw LC, Afzal A, Lewin AS, Timmers AM, Spoerri PE, et al. (2003) Decreased expression of the insulin-like growth factor 1 receptor by ribozyme cleavage. Invest Ophthalmol Vis Sci 44: 4105–4113.
[10]
Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12: 589–603.
[11]
Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57–67.
[12]
Burfeind P, Chernicky CL, Rininsland F, Ilan J (1996) Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 93: 7263–7268.
[13]
Liu X, Turbyville T, Fritz A, Whitesell L (1998) Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Research 58: 5432–5438.
[14]
Samani AA, Fallavollita L, Jaalouk DE, Galipeau J, Brodt P (2001) Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. Hum Gene Ther 12: 1969–1977.
[15]
Scotlandi K, Maini C, Manara MC, Benini S, Serra M, et al. (2002) Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 9: 296–307.
[16]
Chernicky CL, Tan H, Yi L, Loret de Mola JR, Ilan J (2002) Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 55: 102–109.
[17]
Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, et al. (1996) Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 42: 64–68.
[18]
Baserga R, Resnicoff M, Dews M (1997) The IGF-I receptor and cancer. Endocrine 7: 99–102.
[19]
Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9: 753–768.
[20]
Resnicoff M (1998) Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Int J Mol Med 1: 883–888.
[21]
Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, et al. (2004) Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23: 5161–5174.
[22]
Schillaci R, Salatino M, Cassataro J, Proietti CJ, Giambartolomei GH, et al. (2006) Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. J Immunol 176: 3426–3437.
[23]
Lafarge-Frayssinet C, Duc HT, Frayssinet C, Sarasin A, Anthony D, et al. (1997) Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression. Cancer Gene Ther 4: 276–285.
[24]
Ly A, Duc HT, Kalamarides M, Trojan LA, Pan Y, et al. (2001) Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 54: 230–239.
[25]
Ly A, Francois JC, Upegui-Gonzalez LC, Swiercz B, Bedel C, et al. (2000) Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. Life Sci 68: 307–319.
[26]
Institute of Laboratory Animal Research CoLS, National Research Council (1996) Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academic Press. pp. 1–140.
[27]
Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, et al. (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16: 333–350.
[28]
Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Diaz Flaque MC, et al. (2009) Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 29: 1249–1265.
[29]
Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, et al. (2008) TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Experimental Cell Research 314: 509–529.
Robbins M, Judge A, Maclachlan I (2009) siRNA and innate immunity. Oligonucleotides 19: 89–102.
[32]
Chernolovskaya EL, Zenkova MA (2010) Chemical modification of siRNA. Curr Opin Mol Ther 12: 158–167.
[33]
Yeh AH, Bohula EA, Macaulay VM (2006) Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 25: 6574–6581.
[34]
Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, et al. (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19: 2189–2200.
[35]
Trojan J, Ly A, Wei MX, Bierwagen M, Kopinski P, et al. (2010) Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients. Biomed Pharmacother 64: 576–578.
[36]
Cornelie S, Hoebeke J, Schacht AM, Bertin B, Vicogne J, et al. (2004) Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J Biol Chem 279: 15124–15129.
Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, et al. (2009) Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 8: 1448–1459.
[39]
Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12: 90–100.
[40]
Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, et al. (2009) Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition. Clin Cancer Res 15: 7634–7641.
[41]
Balana ME, Labriola L, Salatino M, Movsichoff F, Peters G, et al. (2001) Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20: 34–47.
[42]
Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, et al. (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463–2469.
[43]
Baserga R (1996) Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 14: 150–152.
[44]
Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, et al. (1994) Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 54: 4848–4850.
[45]
Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R (1995) Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55: 3739–3741.
[46]
Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105–126.
[47]
Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361–371.
[48]
Pusztai L, Lewis CE, McGee JO (1993) Growth arrest of the breast cancer cell line, T47D, by TNF alpha; cell cycle specificity and signal transduction. Br J Cancer 67: 290–296.
[49]
Yu P, Lee Y, Liu W, Chin RK, Wang J, et al. (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5: 141–149.
[50]
Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM (2009) Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 8: 2655–2663.
[51]
Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87: 401–406.
[52]
Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, et al. (2006) Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 97: 1044–1049.
[53]
Khatib AM, Auguste P, Fallavollita L, Wang N, Samani A, et al. (2005) Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 167: 749–759.
[54]
Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135–141.
[55]
Blankenstein T (2005) The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17: 180–186.
[56]
Liu F, Hu X, Zimmerman M, Waller JL, Wu P, et al. (2011) TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One 6: e16241.
[57]
Lu Y, Yamauchi N, Koshita Y, Fujiwara H, Sato Y, et al. (2001) Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther 8: 499–507.
[58]
Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H (2000) Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 164: 3645–3651.
[59]
O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, et al. (2008) Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cellular Immunology 252: 91–110.
[60]
Smith TJ (2010) Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 62: 199–236.
[61]
McCusker RH, Strle K, Broussard SR, Dantzer R, Bluthé RM, et al. (2006) Crosstalk between Insulin-like Growth Factors and Pro-inflammatory Cytokines. In: Ader R, editor. pp. 171–192. Psychoneuroimmunology, Fourth Ed Amsterdam, The Netherlands.
[62]
Goes N, Urmson J, Vincent D, Ramassar V, Halloran PF (1996) Effect of recombinant human insulin-like growth factor-1 on the inflammatory response to acute renal injury. J Am Soc Nephrol 7: 710–720.
[63]
Kooijman R (2006) Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 17: 305–323.
[64]
Shen WH, Zhou JH, Broussard SR, Freund GG, Dantzer R, et al. (2002) Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 62: 4746–4756.
[65]
Venters HD, Dantzer R, Kelley KW (2000) Tumor necrosis factor-alpha induces neuronal death by silencing survival signals generated by the type I insulin-like growth factor receptor. Ann N Y Acad Sci 917: 210–220.
[66]
Shalita-Chesner M, Katz J, Shemer J, Werner H (2001) Regulation of insulin-like growth factor-I receptor gene expression by tumor necrosis factor-alpha and interferon-gamma. Mol Cell Endocrinol 176: 1–12.
[67]
Eichbaum C, Meyer AS, Wang N, Bischofs E, Steinborn A, et al. (2011) Breast Cancer Cell-derived Cytokines, Macrophages and Cell Adhesion: Implications for Metastasis. Anticancer Res 31: 3219–3227.
[68]
Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, et al. (2011) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. DOI:10.1007/s10549-011-1540-0.
[69]
Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129–138.
[70]
Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, et al. (2010) Rational design of immunostimulatory siRNAs. Mol Ther 18: 785–795.
[71]
Pastor F, Kolonias D, Giangrande PH, Gilboa E (2010) Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465: 227–230.
[72]
Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, et al. (2011) Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer 128: 216–226.
[73]
Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, et al. (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231–2244.
